Renalase (RNLS) is a recently discovered protein, which plays different roles inside and outside cells. Intracellular RNLS is a FAD-dependent oxidoreductase (EC 1.6.3.5), while extracellular RNLS lacks its N-terminal peptide, FAD cofactor, and exhibits various protective effects in a non-catalytic manner. Certain evidence exists, that plasma/serum RNLS is not an intact protein secreted into the extracellular space, and exogenous recombinant RNLS is effectively degraded during short-term incubation with human plasma samples. Some synthetic analogues of the RNLS sequence (e.g. the Desir's peptide RP-220, a 20-mer peptide corresponding to the RNLS sequence 220–239) have effects on cell survival. This suggests that RNLS-derived peptides, formed during proteolytic processing, may have own biological activity. Based on results of a recent bioinformatics analysis of potential cleavage sites of RNLS (Fedchenko et al., Medical Hypotheses, 2022) we have investigated the effect of four RNLS-derived peptides as well as RP-220 and its fragment (RP-224) on the viability of two cancer cell lines: HepG₂ (human hepatoma) and PC3 (prostate cancer). Two RNLS-derived peptides (RP-207 and RP-220) decreased the viability of HepG₂ cells in a concentration dependent manner. The most pronounced and statistically significant effect (30–40% inhibition of cell growth) was observed at 50 μM concentration of each peptide. In the experiments with PC3 cells five of six RNLS-derived peptides had a significant impact on the cell viability. RP-220 and RP-224 decreased cell viability; however, no concentration dependence of this effect was observed in the range of concentrations studied (1–50 μM). Three other RNLS-derived peptides (RP-207, RP-233, and RP-265) increased viability of PC3 cells by 20–30%, but no concentration-dependence of this effect was found. Data obtained suggest that some RNLS-derived peptides may influence the viability of various cells and manifestation and direction of the effect (increase of decrease of the cell viability) is cell-type-specific.
Fedchenko V.I., Morozevich G.E., Medvedev A.E. (2023) The effect of renalase-derived peptides on viability of HepG₂ and PC3 cells. Biomeditsinskaya Khimiya, 69(3), 184-187.
Fedchenko V.I. et al. The effect of renalase-derived peptides on viability of HepG₂ and PC3 cells // Biomeditsinskaya Khimiya. - 2023. - V. 69. -N 3. - P. 184-187.
Fedchenko V.I. et al., "The effect of renalase-derived peptides on viability of HepG₂ and PC3 cells." Biomeditsinskaya Khimiya 69.3 (2023): 184-187.
Fedchenko, V. I., Morozevich, G. E., Medvedev, A. E. (2023). The effect of renalase-derived peptides on viability of HepG₂ and PC3 cells. Biomeditsinskaya Khimiya, 69(3), 184-187.
References
Xu J., Li G., Wang P., Velazquez H., Yao X., Li Y., Wu Y., Peixoto A., Crowley S., Desir G.V. (2005) Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J. Clin. Invest., 115(5), 1275-1280. CrossRef Scholar google search
Medvedev A.E., Veselovsky A.V., Fedchenko V.I. (2010) Renalase, a new secretory enzyme responsible for selective degradation of catecholamines: Achievements and unsolved problems. Biochemistry (Moscow), 75(8), 951-958. CrossRef Scholar google search
Baroni S., Milani M., Pandini V., Pavesi G., Horner D., Aliverti A. (2013) Is renalase a novel player in catecholaminergic signaling? The mystery of the catalytic activity of an intriguing new flavoenzyme. Curr. Pharm. Des., 19, 2540-2551. CrossRef Scholar google search
Desir G.V., Peixoto A.J. (2014) Renalase in hypertension and kidney disease. Nephrol. Dial. Transplant., 29(1), 22-28. CrossRef Scholar google search
Moran G.R. (2016) The catalytic function of renalase: A decade of phantoms. Biochim. Biophys. Acta, 1864(1), 177-186. CrossRef Scholar google search
Beaupre B.A., Hoag M.R., Roman J., Forsterling F.H., Moran G.R. (2015) Metabolic function for human renalase: Oxidation of isomeric forms of beta-NAD(P)H that are inhibitory to primary metabolism. Biochemistry, 54(3), 795-806.
